Supramodular Nature of GRIP1 Revealed by the Structure of Its PDZ12 Tandem in Complex with the Carboxyl Tail of Fras1
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
High Resolution Genomic Scans Reveal Genetic Architecture Controlling Alcohol Preference in Bidirectionally Selected Rat Model
Purdue University Purdue e-Pubs Department of Animal Sciences Faculty Department of Animal Sciences Publications 2016 High Resolution Genomic Scans Reveal Genetic Architecture Controlling Alcohol Preference in Bidirectionally Selected Rat Model Chiao-Ling Lo Indiana University School of Medicine Amy C. Lossie Indiana University School of Medicine Tiebing Liang Indiana University School of Medicine Yunlong Liu Indiana University School of Medicine Xiaoling Xuei Indiana University School of Medicine See next page for additional authors Follow this and additional works at: http://docs.lib.purdue.edu/anscpubs Recommended Citation Lo C-L, Lossie AC, Liang T, Liu Y, Xuei X, Lumeng L, et al. (2016) High Resolution Genomic Scans Reveal Genetic Architecture Controlling Alcohol Preference in Bidirectionally Selected Rat Model. PLoS Genet 12(8): e1006178. https://doi.org/10.1371/ journal.pgen.1006178 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Authors Chiao-Ling Lo, Amy C. Lossie, Tiebing Liang, Yunlong Liu, Xiaoling Xuei, Lawrence Lumeng, Feng C. Zhou, and William M. Muir This article is available at Purdue e-Pubs: http://docs.lib.purdue.edu/anscpubs/19 RESEARCH ARTICLE High Resolution Genomic Scans Reveal Genetic Architecture Controlling Alcohol Preference in Bidirectionally Selected Rat Model Chiao-Ling Lo1,2, Amy C. Lossie1,3¤, Tiebing Liang1,4, Yunlong Liu1,5, Xiaoling Xuei1,6, Lawrence Lumeng1,4, Feng C. Zhou1,2,7*, William -
Genetic and Neurodevelopmental Spectrum Of
Cognitive and behavioural genetics J Med Genet: first published as 10.1136/jmedgenet-2015-103451 on 17 March 2016. Downloaded from ORIGINAL ARTICLE Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy Cyril Mignot,1,2,3 Celina von Stülpnagel,4,5 Caroline Nava,1,6 Dorothée Ville,7 Damien Sanlaville,8,9,10 Gaetan Lesca,8,9,10 Agnès Rastetter,6 Benoit Gachet,6 Yannick Marie,6 G Christoph Korenke,11 Ingo Borggraefe,12 Dorota Hoffmann-Zacharska,13 Elżbieta Szczepanik,14 Mariola Rudzka-Dybała,14 Uluç Yiş,15 Hande Çağlayan,16 Arnaud Isapof,17 Isabelle Marey,1 Eleni Panagiotakaki,18 Christian Korff,19 Eva Rossier,20 Angelika Riess,21 Stefanie Beck-Woedl,21 Anita Rauch,22 Christiane Zweier,23 Juliane Hoyer,23 André Reis,23 Mikhail Mironov,24 Maria Bobylova,24 Konstantin Mukhin,24 Laura Hernandez-Hernandez,25 Bridget Maher,25 Sanjay Sisodiya,25 Marius Kuhn,26 Dieter Glaeser,26 Sarah Weckhuysen,6,27 Candace T Myers,28 Heather C Mefford,28 Konstanze Hörtnagel,29 Saskia Biskup,29 EuroEPINOMICS-RES MAE working group, Johannes R Lemke,30 Delphine Héron,1,2,3,4 Gerhard Kluger,4,5 Christel Depienne1,6 ▸ Additional material is ABSTRACT INTRODUCTION published online only. To view Objective We aimed to delineate the neurodevelopmental The human SYNGAP1 gene on chromosome please visit the journal online (http://dx.doi.org/10.1136/ spectrum associated with SYNGAP1 mutations and to 6p21.3 encodes the synaptic RAS-GTPase-activating jmedgenet-2015-103451). investigate genotype–phenotype correlations. protein 1, a protein of the post-synaptic density Methods We sequenced the exome or screened the exons (PSD) of glutamatergic neurons.12SYNGAP1 inter- For numbered affiliations see end of article. -
RUNNING HEAD: Low Homozygosity in Spanish Sheep
1 RUNNING HEAD: Low homozygosity in Spanish sheep 2 3 Low genome-wide homozygosity in eleven Spanish ovine breeds 4 5 M.G. Luigi 1, T.F. Cardoso 1, 2 , A. Martínez 3, A. Pons 4, L.A. Bermejo 5, J. Jordana 6, J.V. 6 Delgado 3, S. Adán 7, E. Ugarte 8, J. J. Arranz 9, J. Casellas 6 and M. Amills 1, 6 * 7 8 1Department of Animal Genetics, Centre for Research in Agricultural Genomics 9 (CRAG), CSIC-IRTA-UAB-UB, Campus Universitat Autònoma de Barcelona, 10 Bellaterra 08193, Spain; 2CAPES Foundation, Ministry of Education of Brazil, Brasilia 11 D. F., 70.040-020, Brazil; 3Departamento de Genética, Universidad de Córdoba, 12 Córdoba 14071, Spain; 4Unitat de Races Autòctones, Servei de Millora Agrària i 13 Pesquera (SEMILLA), Son Ferriol 07198, Spain; 5Departamento de Ingeniería, 14 Producción y Economía Agrarias, Universidad de La Laguna, 38071 La Laguna, 15 Tenerife, Spain; 6Departament de Ciència Animal i dels Aliments, Facultat de 16 Veterinària, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain; 7Federación 17 de Razas Autóctonas de Galicia (BOAGA), Pazo de Fontefiz, 32152 Coles. Ourense, 18 Spain; 8Neiker-Tecnalia, Campus Agroalimentario de Arkaute, apdo 46 E-01080 19 Vitoria-Gazteiz (Araba), Spain; 9Departamento de Producción Animal, Universidad de 20 León, León 24071, Spain. 21 22 Corresponding author: Marcel Amills. Department of Animal Genetics, Centre for 23 Research in Agricultural Genomics (CRAG), CSIC-IRTA-UAB-UB, Campus 24 Universitat Autònoma de Barcelona, Bellaterra 08193, Spain. Tel. 34 93 5636600. E- 25 mail: [email protected]. 26 Abstract 27 28 The population of Spanish sheep has decreased from 24 to 15 million heads in 29 the last 75 years due to multiple social and economic factors. -
GRIPAP1 / GRASP1 Antibody (N-Terminus) Goat Polyclonal Antibody Catalog # ALS14943
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 GRIPAP1 / GRASP1 Antibody (N-Terminus) Goat Polyclonal Antibody Catalog # ALS14943 Specification GRIPAP1 / GRASP1 Antibody (N-Terminus) - Product Information Application IHC Primary Accession Q4V328 Reactivity Human Host Goat Clonality Polyclonal Calculated MW 96kDa KDa GRIPAP1 / GRASP1 Antibody (N-Terminus) - Additional Information Gene ID 56850 Anti-GRIPAP1 / GRASP1 antibody IHC of Other Names human brain, cortex. GRIP1-associated protein 1, GRASP-1, GRIPAP1, KIAA1167 Target/Specificity Human GRIPAP1 / GRASP1. This antibody is expected to recognize both reported isoforms (as represented by NP_064522.3; NP_997555.1) Reconstitution & Storage Store at -20°C. Minimize freezing and thawing. Precautions GRIPAP1 / GRASP1 Antibody (N-Terminus) is for research use only and not for use in Anti-GRIPAP1 / GRASP1 antibody IHC of diagnostic or therapeutic procedures. human tonsil. GRIPAP1 / GRASP1 Antibody (N-Terminus) GRIPAP1 / GRASP1 Antibody (N-Terminus) - Protein Information - References Bechtel S.,et al.BMC Genomics Name GRIPAP1 (HGNC:18706) 8:399-399(2007). Ross M.T.,et al.Nature 434:325-337(2005). Synonyms KIAA1167 Hirosawa M.,et al.DNA Res. 6:329-336(1999). Function Lubec G.,et al.Submitted (DEC-2008) to Regulates the endosomal recycling back to UniProtKB. the neuronal plasma membrane, possibly Holt L.J.,et al.Nucleic Acids Res. by connecting early and late recycling 28:72-72(2000). endosomal domains and promoting Page 1/2 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 segregation of recycling endosomes from early endosomal membranes. -
Supplementary Table 8. Cpcp PPI Network Details for Significantly Changed Proteins, As Identified in 3.2, Underlying Each of the Five Functional Domains
Supplementary Table 8. cPCP PPI network details for significantly changed proteins, as identified in 3.2, underlying each of the five functional domains. The network nodes represent each significant protein, followed by the list of interactors. Note that identifiers were converted to gene names to facilitate PPI database queries. Functional Domain Node Interactors Development and Park7 Rack1 differentiation Kcnma1 Atp6v1a Ywhae Ywhaz Pgls Hsd3b7 Development and Prdx6 Ncoa3 differentiation Pla2g4a Sufu Ncf2 Gstp1 Grin2b Ywhae Pgls Hsd3b7 Development and Atp1a2 Kcnma1 differentiation Vamp2 Development and Cntn1 Prnp differentiation Ywhaz Clstn1 Dlg4 App Ywhae Ywhab Development and Rac1 Pak1 differentiation Cdc42 Rhoa Dlg4 Ctnnb1 Mapk9 Mapk8 Pik3cb Sod1 Rrad Epb41l2 Nono Ltbp1 Evi5 Rbm39 Aplp2 Smurf2 Grin1 Grin2b Xiap Chn2 Cav1 Cybb Pgls Ywhae Development and Hbb-b1 Atp5b differentiation Hba Kcnma1 Got1 Aldoa Ywhaz Pgls Hsd3b4 Hsd3b7 Ywhae Development and Myh6 Mybpc3 differentiation Prkce Ywhae Development and Amph Capn2 differentiation Ap2a2 Dnm1 Dnm3 Dnm2 Atp6v1a Ywhab Development and Dnm3 Bin1 differentiation Amph Pacsin1 Grb2 Ywhae Bsn Development and Eef2 Ywhaz differentiation Rpgrip1l Atp6v1a Nphp1 Iqcb1 Ezh2 Ywhae Ywhab Pgls Hsd3b7 Hsd3b4 Development and Gnai1 Dlg4 differentiation Development and Gnao1 Dlg4 differentiation Vamp2 App Ywhae Ywhab Development and Psmd3 Rpgrip1l differentiation Psmd4 Hmga2 Development and Thy1 Syp differentiation Atp6v1a App Ywhae Ywhaz Ywhab Hsd3b7 Hsd3b4 Development and Tubb2a Ywhaz differentiation Nphp4 -
Artificial Intelligence-Based Computational Framework for Drug
Tsuji et al. Alzheimer’s Research & Therapy (2021) 13:92 https://doi.org/10.1186/s13195-021-00826-3 RESEARCH Open Access Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease Shingo Tsuji1*† , Takeshi Hase2,3,4,5†, Ayako Yachie-Kinoshita2,4, Taiko Nishino2,SamikGhosh2, Masataka Kikuchi6, Kazuro Shimokawa7, Hiroyuki Aburatani1, Hiroaki Kitano2 and Hiroshi Tanaka3 Abstract Background: Identifying novel therapeutic targets is crucial for the successful development of drugs. However, the cost to experimentally identify therapeutic targets is huge and only approximately 400 genes are targets for FDA-approved drugs. As a result, it is inevitable to develop powerful computational tools that can identify potential novel therapeutic targets. Fortunately, the human protein-protein interaction network (PIN) could be a useful resource to achieve this objective. Methods: In this study, we developed a deep learning-based computational framework that extracts low-dimensional representations of high-dimensional PIN data. Our computational framework uses latent features and state-of-the-art machine learning techniques to infer potential drug target genes. Results: We applied our computational framework to prioritize novel putative target genes for Alzheimer’s disease and successfully identified key genes that may serve as novel therapeutic targets (e.g., DLG4, EGFR, RAC1, SYK, PTK2B, SOCS1). Furthermore, based on these putative targets, we could infer repositionable -
47421 SAP102 (A7R8L) Rabbit Mab
Revision 1 C 0 2 - t SAP102 (A7R8L) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] 1 Support: 877-678-TECH (8324) 2 4 Web: [email protected] 7 www.cellsignal.com 4 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP H M R Endogenous 102 Rabbit Q92796 1741 Product Usage Information 1. Cuthbert, P.C. et al. (2007) J Neurosci 27, 2673-82. 2. Makino, K. et al. (1997) Oncogene 14, 2425-33. Application Dilution 3. Masuko, N. et al. (1999) J Biol Chem 274, 5782-90. 4. Lau, L.F. et al. (1996) J Biol Chem 271, 21622-8. Western Blotting 1:1000 5. Yan, J. et al. (2005) Mol Psychiatry 10, 329-32. Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity SAP102 (A7R8L) Rabbit mAb recognizes endogenous levels of total SAP102 protein. Species Reactivity: Human, Mouse, Rat Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human SAP102 protein. Background Synapse-associated protein 102 (SAP102, DLG3) belongs to the membrane-associated guanylate kinase (MAGUK) protein family and is a homolog of the Drosophila disc large (dlg) tumor suppressor protein. SAP102 consists of three PDZ domains, a Src homology 3 (SH3) domain, and a guanylate kinase (GK) domain (1). -
LGI1–ADAM22–MAGUK Configures Transsynaptic Nanoalignment for Synaptic Transmission and Epilepsy Prevention
LGI1–ADAM22–MAGUK configures transsynaptic nanoalignment for synaptic transmission and epilepsy prevention Yuko Fukataa,b,1, Xiumin Chenc,d,1, Satomi Chikenb,e, Yoko Hiranoa,f, Atsushi Yamagatag, Hiroki Inahashia, Makoto Sanboh, Hiromi Sanob,e, Teppei Gotoh, Masumi Hirabayashib,h, Hans-Christian Kornaui,j, Harald Prüssi,k, Atsushi Nambub,e, Shuya Fukail, Roger A. Nicollc,d,2, and Masaki Fukataa,b,2 aDivision of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Aichi 444-8787, Japan; bDepartment of Physiological Sciences, School of Life Science, SOKENDAI (The Graduate University for Advanced Studies), Aichi 444-8585, Japan; cDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158; dDepartment of Physiology, University of California, San Francisco, CA 94158; eDivision of System Neurophysiology, Department of System Neuroscience, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Aichi 444-8585, Japan; fDepartment of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan; gLaboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research, Kanagawa 230-0045, Japan; hCenter for Genetic Analysis of Behavior, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki 444-8787, Japan; iGerman Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany; jNeuroscience Research Center, Cluster NeuroCure, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; kDepartment of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; and lDepartment of Chemistry, Graduate School of Science, Kyoto University, 606-8502 Kyoto, Japan Contributed by Roger A. Nicoll, December 1, 2020 (sent for review October 29, 2020; reviewed by David S. -
GRIP1 Gene Glutamate Receptor Interacting Protein 1
GRIP1 gene glutamate receptor interacting protein 1 Normal Function The GRIP1 gene provides instructions for making a protein that is able to attach (bind) to other proteins and is important for moving (targeting) proteins to the correct location in cells. For example, the GRIP1 protein targets two proteins called FRAS1 and FREM2 to the correct region of the cell so that they can form a group of proteins known as the FRAS/FREM complex. This complex is found in the thin, sheet-like structures ( basement membranes) that separate and support the cells of many tissues. The complex is particularly important during development before birth. One of its roles is to anchor the top layer of skin by connecting the basement membrane of the top layer to the layer of skin below. The FRAS/FREM complex is also involved in the proper development of certain other organs and tissues, including the kidneys, although the mechanism is unclear. In addition, the GRIP1 protein targets necessary proteins to the junctions (synapses) between nerve cells (neurons) in the brain where cell-to-cell communication occurs. GRIP1 may also be involved in the development of neurons. Health Conditions Related to Genetic Changes Fraser syndrome At least two GRIP1 gene mutations have been found to cause Fraser syndrome; these mutations are involved in a small percentage of cases of this condition. Fraser syndrome affects development before birth and is characterized by eyes that are completely covered by skin (cryptophthalmos), fusion of the skin between the fingers and toes (cutaneous syndactyly), and abnormalities of the kidneys and other organs and tissues. -
GRIP1 Regulates Synaptic Plasticity and Learning and Memory
GRIP1 regulates synaptic plasticity and learning and memory Han L. Tana,1, Shu-Ling Chiua,b,1, Qianwen Zhua,1, and Richard L. Huganira,2 aSolomon H. Snyder Department of Neuroscience and Kavli Neuroscience Discovery Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205; and bInstitute of Cellular and Organismic Biology, Academia Sinica, 11529 Taipei, Taiwan Contributed by Richard L. Huganir, August 18, 2020 (sent for review July 15, 2020; reviewed by Lin Mei and Peter Penzes) Hebbian plasticity is a key mechanism for higher brain functions, plasticity. For example, synapse-associated protein (SAP97) directly such as learning and memory. This form of synaptic plasticity primarily binds the GluA1 subunit and may promote AMPAR trafficking and involves the regulation of synaptic α-amino-3-hydroxy-5-methyl-4-isoxa- LTP (11–13). Protein interacting with C-kinase 1 (PICK1), a zolepropionic acid receptor (AMPAR) abundance and properties, whereby GluA2 subunit-binding protein, functions to remove AMPAR AMPARs are inserted into synapses during long-term potentiation (LTP) from synapses and causes internalization of synaptic AMPARs, or removed during long-term depression (LTD). The molecular mecha- and deficits in Hebbian plasticity have been reported in PICK1 nisms underlying AMPAR trafficking remain elusive, however. Here we mutant mice (14, 15). show that glutamate receptor interacting protein 1 (GRIP1), an AMPAR- Glutamate receptor interacting protein (GRIP1) is a scaf- binding protein shown to regulate the trafficking and synaptic targeting folding protein that has seven postsynaptic density 95/discs large/ of AMPARs, is required for LTP and learning and memory. GRIP1 is zona occludens (PDZ) domains (16, 17). -
Meta-Analytical Biomarker Search of EST Expression Data Reveals Three
Wu et al. BMC Genomics 2012, 13(Suppl 7):S12 http://www.biomedcentral.com/1471-2164/13/S7/S12 PROCEEDINGS Open Access Meta-analytical biomarker search of EST expression data reveals three differentially expressed candidates Timothy H Wu1, Lichieh J Chu2, Jian-Chiao Wang3, Ting-Wen Chen2,4, Yin-Jing Tien5, Wen-Chang Lin1,6, Wailap V Ng1,3,7* From Asia Pacific Bioinformatics Network (APBioNet) Eleventh International Conference on Bioinformatics (InCoB2012) Bangkok, Thailand. 3-5 October 2012 Abstract Background: Researches have been conducted for the identification of differentially expressed genes (DEGs) by generating and mining of cDNA expressed sequence tags (ESTs) for more than a decade. Although the availability of public databases make possible the comprehensive mining of DEGs among the ESTs from multiple tissue types, existing studies usually employed statistics suitable only for two categories. Multi-class test has been developed to enable the finding of tissue specific genes, but subsequent search for cancer genes involves separate two-category test only on the ESTs of the tissue of interest. This constricts the amount of data used. On the other hand, simple pooling of cancer and normal genes from multiple tissue types runs the risk of Simpson’s paradox. Here we presented a different approach which searched for multi-cancer DEG candidates by analyzing all pertinent ESTs in all categories and narrowing down the cancer biomarker candidates via integrative analysis with microarray data and selection of secretory and membrane protein genes as well as incorporation of network analysis. Finally, the differential expression patterns of three selected cancer biomarker candidates were confirmed by real-time qPCR analysis. -
Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
Autism and Intellectual Disability TRIO Panel Test Code TR002 Test Summary This test analyzes 2429 genes that have been associated with Autism and Intellectual Disability and/or disorders associated with Autism and Intellectual Disability with the analysis being performed as a TRIO Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing Comprehensive test for patients with intellectual disability or global developmental delays (Moeschler et al 2014 PMID: 25157020). Comprehensive test for individuals with multiple congenital anomalies (Miller et al. 2010 PMID 20466091). Patients with autism/autism spectrum disorders (ASDs). Suspected autosomal recessive condition due to close familial relations Previously negative karyotyping and/or chromosomal microarray results. Test Description This panel analyzes 2429 genes that have been associated with Autism and ID and/or disorders associated with Autism and ID. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Autism Spectrum Disorder (ASD) refers to a group of developmental disabilities that are typically associated with challenges of varying severity in the areas of social interaction, communication, and repetitive/restricted behaviors.